A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough
Phase of Trial: Phase II
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 22 Sep 2016 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Aug 2016.
- 27 May 2016 Planned End Date changed from 1 May 2016 to 1 Jul 2016.